BioSpace News Archive

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported its second quarter 2022 financial results and highlighted recent corporate progress.

Resverlogix Corp. announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr. Norman Wong is retiring as CSO.

Skylight Health Group Inc., a multi-state primary care management group in the United States, announced its financial results for the second quarter ended June 30, 2022.

A potential treatment for listeriosis has been found to be promising in Praedicare’s hollow fiber preclinical model of the disease, caused by the bacteria Listeria monocytogenes.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that it has entered into an agreement with Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

Halozyme Therapeutics, Inc., a leader in converting IV biologics to subcutaneous delivery, announced the pricing of $625.0 million aggregate principal amount of convertible senior notes due 2028.

Endure Biotherapeutics, Inc., a leader in the field of engineered microbial therapeutics with the goal of treating gastrointestinal and metabolic disorders, announced the publication of the seminal paper from the laboratory of Amir Zarrinpar, MD, PhD, assistant professor of medicine at UC San Diego, Endure Bio founder and Chief Medical Officer.

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June 30, 2022, and provided an update on recent corporate developments.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at a public offering price of $7.82 per share.